Business News

Benchmark indices Sensex and Nifty ended marginally lower in a volatile trade on Wednesday dragged by blue-chip IT stocksStocks that were in focus include names like Zen Technologies, which rose 10% and Tata Motors, which declined 0.2% and Data Patterns, whose shares gained 9% on Monday.Here's what Riyank Arora, Technical Analyst at Mehta Equities, recommends investors should do with these stocks when the market resumes trading today.Zen TechnologiesThe stock witnessed a good breakdown below its major support levels of 1180 and currently rebounding from lower zones. A re-test to the 1150-1200 zone should trigger the next downside move.Overall we recommend investors to trim down their positions as stock can move lower towards 900 odd levels.Tata MotorsThe stock has its major support at 650 levels and we expect automotive stocks to witness a good rebound from lower levels.On the upside, the stock can go towards 720-750 odd levels once the uptrend resumes. A strict stoploss to be kept at 650 mark to be managed risk well.Data PatternsThe stock has witnessed a good break below the major support mark of 1730 and indicating huge negative momentum. Overall the structure of stock is looking to be very negative and stock can go towards 1300 and 1200 id levels.A strict SL can be kept near 1650 to mark to manage risk well in this trade.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Mumbai: Brokerage Macquarie has initiated coverage on Indian contract research, development, and manufacturing (CRDMO) companies catering to global drug makers, and has assigned an 'Outperform' ratings to Divi's Labs, Suven Pharma, Bluejet Healthcare, and Syngene.Their price targets imply an upside of 19-30% for the shares over the next 12 months.Macquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressures and geopolitical factors, prompting a global restructuring of the pharmaceutical supply chain."We believe favourable geopolitical dynamics, ease of doing business, and strong IP(intellectual property) protection laws further enhance India's position as a preferred partner for pharmaceutical R&D (research and development) and manufacturing," said the brokerage's analysts in a note to their clients.118401248The industry has also benefited from the Inflation Reduction Act in the US, which is putting pressure on pharmaceutical companies to cut costs, and the US Biosecure Act, which has not been passed yet but has prompted US-based companies to move from Chinese to Indian and Korean manufacturers.Macquarie's analysts said that the higher valuations of Indian companies compared to other peers are justified because they also project higher profitability growth in India.